Molina Healthcare, Inc.
MOH Healthcare Medical - Healthcare Plans NYSE
$144.47
$-3.24 (-2.19%)
Open: $149.11 | High: $149.11 | Low: $144.47 | Prev Close: $147.71
Market Cap: $7.44B
Volume: 1.1M | Avg: 1.7M
Last updated: March 09, 2026 at 02:03 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 495
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 16.55 |
| P/B Ratio | 1.80 |
| P/S Ratio | 0.16 |
| EPS | $8.73 |
| Beta | 0.50 |
| Shares Outstanding | 51.50M |
| 52-Week High | $359.97 |
| 52-Week Low | $121.06 |
| SMA 50 | $166.09 |
| SMA 200 | $189.85 |
| Next Earnings | April 22, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 9.0% |
| Operating Margin | 1.7% |
| Net Margin | 1.0% |
| ROE | 11.0% |
| ROA | 3.0% |
| Debt/Equity | 0.97 |
| Current Ratio | 1.69 |
| Quick Ratio | 1.69 |
Balance Sheet
| Total Assets | $15.56B |
| Total Liabilities | $11.49B |
| Total Equity | $4.07B |
|
|
|
| Cash | $4.25B |
| Total Debt | $3.95B |
| Net Debt | $-298,000,000 |
Income Statement
| Revenue | $45.43B |
| Gross Profit | $4.08B |
| Operating Income | $781.00M |
| Net Income | $472.00M |
|
|
|
| EBITDA | $976.00M |
| Revenue/Share | $894.32 |
Cash Flow
| Operating CF | $-535,000,000 |
| CapEx | $101.00M |
| Free Cash Flow | $-636,000,000 |
|
|
|
| Book Value/Share | $80.11 |
| Tangible Book/Share | $36.89 |
| Equity/Share | $80.11 |
Technical Indicators
| RSI (14) | 64.70 Neutral |
| MACD |
-4.59
Signal: -6.26
|
| Volatility | 94.88% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -55.6% |
| Sharpe Ratio | -1.32 Poor |
| Volatility (Ann.) | 62.3% High Risk |
| MOH (1Y) | -55.6% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -68.63% |
Sector Comparison (Healthcare)
| Metric | MOH | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 16.55 | 27.87 | 21% |
| P/B Ratio | 1.8 | -19.56 | 32% |
| ROE (%) | 10.99% | -9.50% | 43% |
| Net Margin (%) | 1.04% | 9.48% | 15% |
| Stock Score | 495 | 544.0 | 25% |
| 1Y Return (%) | -55.60 % | +9.39 % | 0% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOH | $144.47 | $147.64 | $147.92 | $147.41 | $165.82 | $189.78 | 64.70 | -4.59 | 94.88% | 198796 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the MOH stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| MOH | Molina Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Molina Healthcare, Inc. - MOH | Neutral | businesswire.com | Read More |
| MOH | Stock Market Today: Futures Plunge as Oil Tops $100/Barrel; Treasury Yields Jump on Stagflation Fears; Dollar Strengthens | Neutral | investopedia.com | Read More |
| MOH | Molina Healthcare, Inc. (MOH) Presents at TD Cowen 46th Annual Health Care Conference Transcript | Neutral | seekingalpha.com | Read More |
| MOH | Molina Healthcare Announces First Quarter 2026 Earnings Release and Conferences Call Dates and Investor Day Meeting | Neutral | businesswire.com | Read More |
| MOH | Molina Healthcare of Florida Announces a $70,000 Grant Funding NAMI's Behavioral Health Peer Mentor Program | Neutral | businesswire.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-12 | ROMNEY RONNA | director | SELL | 506 | $146.92 | $74342 |
| 2026-03-01 | Zubretsky Joseph M | director, officer: President & CEO | BUY | 66417 | $145.75 | $9680278 |
| 2026-03-01 | Zubretsky Joseph M | director, officer: President & CEO | SELL | 8597 | $154.05 | $1324368 |
| 2026-03-01 | Keim Mark Lowell | officer: Chief Financial Officer | BUY | 26073 | $145.75 | $3800140 |
| 2026-03-01 | Keim Mark Lowell | officer: Chief Financial Officer | SELL | 2308 | $154.05 | $355547 |
| 2026-03-01 | WOYS JAMES | officer: Chief Operating Officer | BUY | 17016 | $145.75 | $2480082 |
| 2026-03-01 | WOYS JAMES | officer: Chief Operating Officer | SELL | 1313 | $154.05 | $202268 |
| 2026-03-01 | HEBERT MAURICE | officer: Chief Accounting Officer | BUY | 2058 | $145.75 | $299954 |
| 2026-03-01 | HEBERT MAURICE | officer: Chief Accounting Officer | BUY | 650 | $154.05 | $100133 |
| 2026-03-01 | HEBERT MAURICE | officer: Chief Accounting Officer | SELL | 229 | $154.05 | $35277 |
Company Information
Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.
| CEO | Joseph Michael Zubretsky |
| Employees | 18000 |
| Country | US |
| IPO Date | 2003-07-02 |
| Exchange | NYSE |
| Website | https://www.molinahealthcare.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
Similar Stocks (Healthcare - Medical - Healthcare Plans)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category